scholarly journals CN5 - COST-EFFECTIVENESS OF PEMBROLIZUMAB VERSUS STANDARD-OF-CARE CHEMOTHERAPIES FOR FIRST-LINE TREATMENT OF PD-L1 POSITIVE (≥50%) METASTATIC NON-SMALL CELL LUNG CANCER IN FRANCE

2018 ◽  
Vol 21 ◽  
pp. S4
Author(s):  
C. Chouaid ◽  
L. Bensimon ◽  
E. Clay ◽  
A. Millier ◽  
L. Lévy-Bachelot ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cost Effectiveness ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Standard Of Care ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
First Line ◽  
First Line Treatment

scholarly journals Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients WithEGFR-Mutated Advanced Non–Small Cell Lung Cancer

JAMA Oncology ◽  
2018 ◽  
Vol 4 (8) ◽  
pp. 1080 ◽  
Author(s):  
Pedro N. Aguiar ◽  
Benjamin Haaland ◽  
Wungki Park ◽  
Pui San Tan ◽  
Auro del Giglio ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cost Effectiveness ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
First Line ◽  
First Line Treatment
Sign in / Sign up

Export Citation Format

Share Document